toceranib phosphate

 

Topic mentions per year

Topic mentions per year

2009-2018
024620092018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Objectives The aim of the study was to determine the clinical benefit and adverse event profile of toceranib phosphate in the… (More)
  • table 1
  • figure 2
  • figure 1
  • table 2
  • table 3
Is this relevant?
2016
2016
While maintaining a standard toceranib dosage [2.75 mg kg(-1) , PO, every other day (EOD)], three dose-escalating CCNU cohorts up… (More)
Is this relevant?
2015
2015
BACKGROUND Nonresectable mast cell tumors (MCT) in dogs remain a therapeutic challenge, and investigation of novel combination… (More)
  • table 1
  • table 2
  • table 3
  • table 5
  • figure 1
Is this relevant?
2013
2013
BACKGROUND The receptor kinase inhibitor toceranib phosphate (Palladia) was approved for use in dogs in 2009 using a dose of 3.25… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2012
2012
The purpose of this study was to provide an initial assessment of the potential biologic activity of toceranib phosphate… (More)
Is this relevant?
2012
2012
Combining drugs with known single-agent activity that lack overlapping dose-limiting toxicities (DLT) and exert antitumour… (More)
Is this relevant?
2012
2012
Toceranib phosphate and piroxicam have individually demonstrated antineoplastic activity. Additionally, non-steroidal anti… (More)
Is this relevant?
2012
2012
Palladia(TM) (toceranib phosphate-Pfizer Animal Health) is a novel orally administered receptor tyrosine kinase inhibitor (TKI… (More)
Is this relevant?
2010
2010
Toceranib phosphate (Palladia, SU11654), an oral tyrosine-kinase inhibitor, is under investigation for the treatment of mast cell… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell… (More)
Is this relevant?